Apr 05, 2012, 10.58 PM | Source: CNBC-TV18
Bio-pharma major Biocon on expansion mode.
Biocon is banking on a strong research pipeline. The company's focus on oral insulin will continue.
Kiran Mazumdar-Shaw, chairman and managing director, Biocon
says, the big change in our strategy would be that from having one global partner which was Pfizer, we'll have multiple partners.
Biocon stock price
On April 29, 2016, Biocon closed at Rs 585.55, up Rs 10.65, or 1.85 percent. The 52-week high of the share was Rs 589.50 and the 52-week low was Rs 396.50.
The company's trailing 12-month (TTM) EPS was at Rs 40.44 per share as per the quarter ended March 2016. The stock's price-to-earnings (P/E) ratio was 14.48. The latest book value of the company is Rs 169.62 per share. At current value, the price-to-book value of the company is 3.45.
Rahul Shah of Motilal Oswal is of the view that on
Ashwani Gujral of ashwanigujral.com is of the view
Jay Thakkar of Sharekhan is of the view that one m
Sudarshan Sukhani of s2analytics.com likes Biocon
Amit Gupta of ICICIdirect is of the view that one
Here are a few top buzzing midcap stocks picked up
Amalgamated Electricity Company Ltd has informed B
Vishal Malkan of malkansview.com is of the view th